Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma
Irene M. Ghobrial*, Chia Jen Liu, Oksana Zavidij, Abdel K. Azab, Rachid Baz, Jacob P. Laubach, Yuji Mishima, Philippe Armand, Nikhil C. Munshi, Frank Basile, Michael Constantine, James Vredenburgh, Adam Boruchov, Pamela Crilley, Patrick M. Henrick, Kalvis T.V. Hornburg, Houry Leblebjian, Stacey Chuma, Kaitlen Reyes, Kimberly Noonan
*此作品的通信作者
研究成果: Article › 同行評審
44
引文
斯高帕斯(Scopus)